Slide 1: Stock exchange intimation letter
February 14, 2025 To, To, BSE Limited, Listing Department, 25, P. J. Towers, National Stock Exchange of India Ltd., Dalal Street, Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai- 400051 Ref: Company Scrip Code: 532834 Ref: Symbol: CAMLINFINE || Series: EQ Sub: Intimation
Slide 2: Camlin Fine Sciences Limited Investor Presentation – February 2025
Camlin Fine Sciences Limited Investor Presentation – February 2025
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Camlin Fine Sciences Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Performance Highlights – Q3 FY25
Performance Highlights – Q3 FY25 3
Slide 5: Q3 FY25 Performance Highlights
Q3 FY25 Performance Highlights Revenue (Rs. In Mn) EBITDA* (Rs. In Mn) PAT (Rs. In Mn) 8.4% 10.2% 12.3% Margin 4,230 4,335 3,859 532 432 -143 -75 325 Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 -1,161 Q3FY24 Q2FY25 Q3FY25 Operational Highlights • Consolidated Revenue improves to Rs. 4,335 mn which is
Slide 6: Operational Revenue Breakup
Operational Revenue Breakup Specialty Ingredients (Rs. In Mn) Specialty Ingredients (Rs. In Mn) Total Specialty Ingredients (Rs. In Mn) (Straights) (Value added blends) 3,071 6,390 9,235 2,845 8,240 5,170 1,065 2,259 2,842 3,150 890 1,777 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY2
Slide 7: Regional Highlights
Regional Highlights CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 6,139 3,883 1,858 5,529 3,605 1,856 2,051 1,244 1,360 631 311 142 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY24 9MFY25 CFS Brazil (Rs. In Mn) CFS North America (Rs. In Mn) CFS Vitaf
Slide 8: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. In Mn) Q3 FY25 Q3 FY24 YoY Q2 FY25 QoQ 9MFY25 9MFY24 YoY Revenue from Operation 4,334.9 3,858.9 12.3% 4,229.7 2.5% 12,523.2 12,113.7 3.4% Raw material consumption 2,163.2 2,126.0 2,190.7 6,534.3 6,519.9 Employee Cost 519.6 454.9 522.8 1,554.1 1,3
Slide 9: Standalone Profit & Loss Statement
Standalone Profit & Loss Statement Particulars (Rs. In Mn) Q3 FY25 Q3 FY24 YoY Q2 FY25 QoQ 9MFY25 9MFY24 YoY Revenue from Operation 2,050.7 1,856.1 10.5% 2,269.1 -9.6% 6,139.0 5,529.3 11.0% Raw material consumption 1,012.9 1,076.2 1,306.2 3,339.1 2,786.6 Employee Cost 171.8 162.3 196.0 535.9 494.1 O
Slide 10: Company Overview
Company Overview INGREDIENTS-
Slide 11: Product Highlights
Product Highlights FY24 Sales Mix% Key Products End User Industries Key Brands › TBHQ › Pet Food › Animal Feed Mills Straights 26% › BHA › Livestock Nutrition › Biodiesel › Ascorbyl palmitate (ASP) › Food & Beverages › Aquaculture & Fishmeal › Fish Meal › Rendering Specialty Ingredients › 200+ custo
Slide 12: Innovation at Work
Innovation at Work Process Optimization Initiatives • Vanillin Production Optimization: Continuous improvement at our new Dahej plant, refining processes and setting a future – oriented strategic direction • HQ Derivatives Process: Developed a novel, process with improved selectivity for producing H
Slide 13: Acquisition of Vitafor Invest NV
Acquisition of Vitafor Invest NV • Dresen Quimica SAPI De CV, Mexico has acquired 100% stake in Vitafor Invest Acquisition NV, Belgium and its underlying subsidiaries/associate on June 11, 2024 Details • 100% stake in Target Entity for Cash Consideration of € 1 (Euro One) Key Rationale Brief Backgro
Slide 14: Manufactured In-house
Integration Chain Phenol Hydroquinone Diphenols Catechol Manufactured In-house Performance Performance Specialty Ingredients Chemicals Aroma Ingredients Chemicals Ascorbyl Palmitate1 TBHQ MEHQ Guaiacol Guethol BHA Other derivatives of HQ Veratrole Vanillin Other derivatives of Blends Ethyl Vanillin
Slide 15: ESG
ESG • Main goal by 2030 is to switch to renewable electricity for all manufacturing facilities. Currently, company is exploring different options to achieve this goal Environment • Dedicated to sustainability and done few initiatives from reducing food waste to sourcing clean energy • Constantly see
Slide 16: Board of Directors
Board of Directors Name Profile Ashish Dandekar › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information Chairman & Managing Director systems, research & development, product development, and marketing › Holds a BA in Economics an
Slide 17: Senior Management Team
Senior Management Team Name › Profile Ashish Dandekar › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information Chairman & Managing Director systems, research & development, product development, and marketing › Holds a BA in Econom
Slide 18: Way Forward
Way Forward Specialty Ingredients Aroma Ingredients • Maintaining market leadership for • Introduce specialized and customized Antioxidants products within the vanillin range, catering to diverse application needs • Increasing focus on high margin blends and additives. These formulations are • Activ
Slide 19: Historical Financial Highlights
Historical Financial Highlights
Slide 20: Historical Financial Highlights
Historical Financial Highlights Revenue (Rs. In Mn) EBITDA (Rs. In Mn) PAT (Rs. In Mn) 12.5% 15.3% 10.8% 12.7% 7.0% 2.8% 5.5% 4.3% 2.4% -6.5% Margin 16,816 16,131 14,121 11,871 2,131 654 604 10,168 1,819 298 398 1,528 1,307 1,134 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 -1,049 FY20 FY21 FY2
Slide 21: Operational Revenue Break-Up
Operational Revenue Break-Up Specialty Ingredients (Rs. In Mn) Specialty Ingredients (Rs. In Mn) Total Specialty Ingredients (Rs. In Mn) (Straights) (Value added blends) 11,400 9,679 4,576 7,288 4,111 7,980 3,812 5,103 6,171 2,860 4,168 5,516 2,381 3,135 3,311 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22
Slide 22: Regional Highlights
Regional Highlights CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 7,894 7,733 4,822 4,883 6,855 4,395 5,798 6,000 3,533 3,762 3,198 3,091 2,571 2,735 2,271 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 CFS Brazil (Rs. In Mn) CFS North America (Rs. I
Slide 23: Camlin Fine Sciences Ltd. contact details
Camlin Fine Sciences Ltd. CIN – L74100MH1993PLCO75361 Mr. Santosh Parab- CFO Email – santosh.parab@camlinfs.com www.camlinfs.com Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Shrikant Sangani / Ms. Shaily Patwa Email – shrikant.sangani@sgapl.net / shaily.p@sgapl.net Mobile No –